AIR Insulin: Phase II data

In an open-label, crossover, U.S. Phase II trial in 259 patients, inhaled AIR Insulin met the primary endpoint of non-inferiority to injected insulin. Over 3 months, average HbA1c was 7.9% for AIR Ins...